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The Role of Biotechnology in the CGIAR: 
A Report on the Highlights of a Stakeholders Consultation 
Background 
A major concern has been expressed about the capacity of the CGIAR to 
serve as a link between advanced relsearch institutions including those of the private 
sector at the vanguard of research in agricultural biotechnology, and the national 
agricultural research systems whose efforts directly benefit poor farmers and 
consumers in the South. Biotechnology has evolved to be a powerful and critical 
tool in research to increase agricultural productivity and enhance natural resource 
management. The CGIAR has not only kept a watchful eye on the development in 
the biotechnology research arena but has also actually been a participant in the 
development and utilization of biotechnology techniques and products. The extent to 
which it has been involved relativle to what is necessary is one of the major 
questions being asked. 
A consultation on the role of biotechnology in the CGIAR was convened by 
the CGIAR Chairman on April 18, 1997. The primary objective was to review the 
state-of-the-art in biotechnology research both within and outside the CGIAR 
System, and to discuss the needs and opportunities for CGIAR investments in this 
field. A number of important issues concerning biotechnology were raised and 
discussed. Participants in the consultation were CGIAR stakeholders composed of 
the chairs of various CGIAR committees, and representatives from the private 
sector, NGOs, NARS, member organizations and scientists involved with 
biotechnology research work. The list of participants is attached. 
Biotechnology Research in the CGIAR 
Biotechnology research efforts in the CGIAR were initiated in the mid-70’s by 
two centers, CIP and ILRAD (now ILRI). Today, twelve centers are engaged in 
various research activities involving the use of biotechnology techniques. The 
centers’ laboratories vary in terms of the types of biotechnology techniques being 
employed, i.e. from the relatively simple cell or tissue culture to the more comp!ex 
methods aimed at developing transgenic plants. 
The main areas of the centers’ biotechnology work are in crop disease 
diagnosis/detection, crop improvement, germplasm storage and exchange, crop 
propagation, improvement of microorganisms, livestock disease detection and 
treatment, embryo storage and exchange, and livestock improvement. 
Biotechnology research funding in the centers represents a small fraction of 
the total funding for the CGIAR research agenda. From a survey of the centers 
conducted by the CGIAR Private Sector Committee, the centers’ expenditures for 
biotechnology research reached $22.4 million ($10 million of which was by ILRI) in 
1995. This was double the amount spent in 1993 and accounted for about 7% of 
the total CGIAR research funding. (Some centers have pointed out that their current 
spending is more than what was indicated by the 1995 survey. However, there 
appears to be a consensus that total system’s funding for biotechnology research 
work remains under $25 million). The amount may represent a significant share of 
the total public sector funding (estimated at $50 million) of biotechnology research 
work in the developing countries. This is, however, miniscule compared to the 
estimated $2.5 billion per year investments by public and private sector institutions 
in agri-biotechnology research programs in industrialized countries. The private 
sector investment, in particular, has been increasing at a rapid rate. 
issues Raised and Stakeholders’ Responses 
The consultation was a freewheeling discussion of a number of issues 
pertinent to biotechnology in the CGIAR. The key questions and corresponding 
responses are summarized below. 
l What is the place of biotechnology in the CGIAR in the context of 
carrying out its mission iof “contributing to sustainable agriculture for 
food security in developing countries”? 
There was broad recognition of the potential of biotechnology 
in accelerating agricultural transformation in developing countries. 
Most of the current agri-biotechnology applications in industrialized 
countries are similarly needed in developing countries. Such 
applications as molecular mapping, gene promoters and 
transformation techniaues, to name a few, are useful tools in crop 
improvement work. However, little attention is given by the largest 
investors in biotechnology research work that addresses the research 
priorities of developing countries. The products or technologies 
developed in the North are not tailored to address the specific needs 
in the South, i.e. in terms of plant or animal species, types of 
production constraints (insect pests, diseases, abiotic stresses), etc. 
Therefore, there is a widening gap in the applications of biotechnology 
between rich end poor countries, a technological gap that may create 
greater social and economic inequalities globally, regionally, and 
nationally. 
Consistent with its mission, CGIAR should play a key role in 
reducing this gap. Biotechnology is a powerful tool that would enable 
the CGIAR to enhance greatly its capacity to contribute to a more 
rapid and sustainable agricultural growth in developing countries. 
l Through what modalities should an expanded program in biotechnology 
research in the CGIAR be carried out? 
As pointed out earlier, the levels of agri-biotechnology research 
investments in the developing world are nowhere near those in the 
developed countries. The private sector investments alone in 
developed countries are multiples of the current levels of investment 
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that the public sector, including the CGIAR, is able to make in 
developing countries. The CGIAR should strive to increase its in-house 
capacity for biotechnology research, to ensure that the system has 
the research teams with the necessary wherewithal to effectively 
carry out their work. In parallel, it should also find ways to construct 
new, substantial, and equitable partnerships with advanced research 
institutions and private sector. Such partnerships will be defined by 
the complementary capacities of potential partners. 
Apart from building the system as a research base and a 
platform for collaboration in biotechnology, the CGIAR could also 
serve as a system of knowledge nodes where the most important and 
relevant technological advances are brought together, adapted, and 
disseminated for the benefit of the poor. 
The indications from the NARS on the issue are encouraging. 
The diversity of the NARS in many aspects (priorities, capacities for 
biotechnology research, etc.) is, of course, fulli/ recognized. Some of 
the NARS institutions have developed some level of capacity for 
biotechnology research and are already collaborating with some 
centers and other partners. Many others, however, need assistance 
either in developing their capacity or in accessing biotechnology 
products. 
e What level of investment is necessary? 
Participants recognized the need to increase the amount of 
support to a level that is multiple of the present funding. Clearly, there 
are gaps that need to be filled. The types of biotechnology work that 
need to be expanded have to be identified. The centers’ research 
plans (MTPs) for 1998-2000 might not have adequately reflected the 
needs in terms of a more responsive biotechnology research agenda 
and the required resources to support it. This, according to some of 
the centers, does not imply a “constrained vision” but is seen more as 
a result of financial prudence. 
The consultation made it clear that increasing CGIAR’s 
investments in biotechnology research is not a reallocation of current 
resources. It is based on a firm understanding that they will be 
additional to the support currently provided to the agreed agenda. The 
increased investments should not detract the centers from the other 
important work that they need to do. 
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l How should CGIAR address intellectual property rights (IPR) and biosafety 
issues? 
Any discussion of biotechnology invariably brings up a 
concomitant set of issues, i.e. biosafety and intellectual property 
rights (IPR) issues. Biosafety is important from the standpoint of risks 
prevention and public acceptance of the products of biotechnology. 
This was, among other things, reiterated by the NGO constituency 
particularly with regard to transgenic plants. IPR issues are of major 
concern with respect to maintaining the free exchange of germplasm 
and ensuring access to biotechnology products and techniques for the 
benefit of developing countries. 
The extensive consultations and discussions conducted by 
previous CGIAR panels (BlOTASK in 1991 and Swaminathan’s panel 
on IPR in 1994) have led to the development of an interim set of 
working guidelines on IPR that will be reviewed and revised to take 
into account changes occurring in various fora. Further discussions of 
the issues were held at a workshop on “Ethics and Equity in 
Conservation and Use of Genetic Resources for Food Security” 
organized by the Genetic Resources Policy Committee whose report 
will be available in Cairo. These issues will inevitably come more into 
focus as the system increases its efforts to expand research 
partnerships between the centers and their collaborators in 
biotechnology. 
Overall, the consultation conveyed the following messages: 
. recognizing the potentials of biotechnology as an added tool, the 
CGIAR should proceed with efforts to enhance its capacity for 
biotechnology research with a special emphasis on such 
technologies as molecular markers and a strong link to breeding, 
farm systems a’t the smallholder level and ecological 
considerations, 
0 investment in biotechnology research will need to be increased by 
a significant amount, a multiple of the current allocation, 
. stronger partnerships and collaboration are required within the 
CGIAR System as well as between CGIAR centers and others 
engaged in biotechnology research, 
. the CGIAR should position itself to ensure that advances in 
biotechnology can be harnessed for the benefit of the poor and for 
the protection of the environment; it should vigorously promote 
public awareness of the context in which biotechnology research 
programs are carriecl out. 
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Consultation on the Role of Biotechnology in the CGIAR 
Date / Time: April 18, 1997 I 4:30 p.m. - 7:00 p.m. 
Venue: Room S 7013, The World Bank ‘S” Building 
1750 Pennsylvania Ave., N.W., Washington, D.C. 
List of Participants -- 
Chair: lsmail Serageldin 
Chairman, CGIAR 
Center Directors: Hubert Zandstra 
Chair, Center Directors Committee 
and Director General, CIP 
Tim Reeves 
Director General, CIMMYT 
Center Board 
Chairs: Wanda Collins 
Chair, Center Board Chairs Committee 
Technical Advisory 
Committee: Donald Winkelmann 
Chair, Technical Advisory Committee 
Private Sector 
Commitee: Bernard Auxenfans 
Member, Private Sector Committee 
Vice President, Monsanto Company 
Sam Dryden 
Member, Private Sector Committee 
Managing Directfor, Big Stone Partners 
Non-Governmental 
Organization: Michael Hansen 
Research Associate 
Consumers Policy Institute / Consumers Union 
Genetic Resources 
Policy Committee: Geoffrey Hawtiin 
Member, Genetic Resources Policy Commitee 




Organizations: Alex McCalla 
Director, Agriculture and Natural Resources Dept. 
The World Bank 
Judith Chambers 
Senior Biotechnology Specialist 
USAID 
Gary Toenniessen 
Deputy Director, Agricultural Sciences 
Rockefeller Foundation 
National Agricultural 
Research Systems: Marcio de Miranda Santos 
Head, Department of Research and Development 
EMBRAPA, Brazil 
Scientists: Rudy Rabbinge 
Member, Scientific Council for Government Policy,The Netherlands 
and Chair, Board of Trustees, IRRI 
Fred Gould 
Member, The World Bank Panel On Transgenic Crops 
and Professor, North Carolina State University 
Finance Committee: Michel Petit 
Chairman, Finance Committee 
and Director, Aglricultural Research Group (ESDAR) 
The World Bank 
CGIAR Secretariat: Alexander von der Osten 
Executive Secretary 
Manuel M. Lantin 
Science Adviser 
Ernest Corea 
Senior Information Officer 
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